Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan.
Sci Rep. 2021 Nov 18;11(1):22495. doi: 10.1038/s41598-021-01900-4.
To stratify the heterogeneity of prostate cancer (PCa) with seminal vesicle invasion (SVI) immunologically after radical prostatectomy focusing on the tumor microenvironment. We retrospectively reviewed the clinicopathological data of 71 PCa patients with SVI, which is known as a factor of very high-risk PCa. Preoperative clinical variables and postoperative pathological variables were evaluated as predictors of biochemical recurrence (BCR) with a multivariate logistic regression. Immune cell infiltration including the CD8-positive cell (CD8 cell) and CD204-positive M2-like macrophage (CD204 cell) was investigated by immunohistochemistry. The cumulative incidence and risk of BCR were assessed with a Kaplan-Meier analysis and competing risks regression. A higher CD8 cell count in the SVI area significantly indicated a favorable prognosis for cancers with SVI (p = 0.004). A lower CD204 cell count in the SVI area also significantly indicated a favorable prognosis for cancers with SVI (p = 0.004). Furthermore, the combination of the CD8 and CD204 cell infiltration ratio of the SVI area to the main tumor area was a significant factor for BCR in the patients with the PCa with SVI (p = 0.001). In PCa patients with SVI, the combination of CD8 and CD204 cell infiltration is useful to predict the prognosis.
为了在根治性前列腺切除术后从肿瘤微环境的角度对具有精囊侵犯(SVI)的前列腺癌(PCa)进行免疫学分层,我们回顾性地分析了 71 例具有 SVI 的 PCa 患者的临床病理数据,SVI 是 PCa 极高危因素之一。采用多变量逻辑回归评估术前临床变量和术后病理变量作为生化复发(BCR)的预测因子。通过免疫组织化学研究包括 CD8 阳性细胞(CD8 细胞)和 CD204 阳性 M2 样巨噬细胞(CD204 细胞)在内的免疫细胞浸润。采用 Kaplan-Meier 分析和竞争风险回归评估累积发生率和 BCR 风险。SVI 区域 CD8 细胞计数较高显著提示 SVI 癌症具有良好的预后(p=0.004)。SVI 区域 CD204 细胞计数较低也显著提示 SVI 癌症具有良好的预后(p=0.004)。此外,SVI 区域与主肿瘤区域的 CD8 和 CD204 细胞浸润比率的组合是 SVI 前列腺癌患者 BCR 的显著因素(p=0.001)。在具有 SVI 的 PCa 患者中,CD8 和 CD204 细胞浸润的组合可用于预测预后。